Filing Flows › Comparisons › OMER vs VRDN
Omeros vs Viridian Therapeutics: OMER and VRDN compared
Omeros is the larger company: $28.5M of revenue in its latest quarter (Q2 2026) against $25.8M for Viridian Therapeutics (Q3 2026). Omeros is more profitable, with an operating margin of 0.3% against -401.8%.
Where the money goes: OMER and VRDN
Omeros (OMER) · Q2 2026
Omeros, Q2 2026: revenue $28.5M, operating margin 0.3%, net earnings $13.2M, operating cash flow $4.1M. The chart follows the revenue to costs, profit and cash.
Viridian Therapeutics (VRDN) · Q3 2026
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart follows the revenue to costs, profit and cash.
| Omeros (OMER) | Viridian Therapeutics (VRDN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $28.5M | $25.8M |
| Revenue growth, Y/Y | — | -64% |
| Operating margin | 0.3% | -401.8% |
| Net earnings | $13.2M | −$101M |
| Net margin | 46.4% | -393.0% |
| Operating cash flow | $4.1M | −$92.8M |
| Free cash flow | $4.1M | — |
| Market value | $1.8B | — |
| P/E | 14.4× | — |
| Analysts’ mean target | $27.50 | — |
Where the revenue comes from
Viridian Therapeutics
- Product revenue, net: $24.7M (96%)
- Collaboration revenue: $956K (4%)
- License revenue: $125K (0%)
Questions
Which is bigger, Omeros or Viridian Therapeutics?
Omeros is the larger company: $28.5M of revenue in its latest quarter (Q2 2026) against $25.8M for Viridian Therapeutics (Q3 2026).
Is Omeros or Viridian Therapeutics growing faster?
Omeros is more profitable, with an operating margin of 0.3% against -401.8%.
More: Omeros earnings · how Omeros makes money · Viridian Therapeutics earnings · how Viridian Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.